Evaluation of the clinical effect of Methylprednisolone lozenge in oral lichen planus

Phase 3

• Conditions: Oral lichen planus disease.; Other lichen planus; L43.8

• Registration Number: IRCT20220115053724N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Age 18 to 60 years
Willingness to participate in the study and complete the ethical consent form
Women should not be pregnant or lactating
Not using allopurinol
Not using viral vaccines during treatment
Patients do not have a confirmed history of allergic reactions following the oral intake of methylprednisolone
The patient does not have a low level of consciousness
The patient should not be treated with warfarin
The patient does not have an active viral disease

Exclusion Criteria

Aggravation of oral lichen lesions
Unwillingness to cooperate during treatment
Not using medicine for two consecutive days
Emergence of allergic reaction to methylprednisolone

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Redness and inflammation. Timepoint: At the beginning of treatment and after every 2 to 10 days, the status of oral lichen planus lesions is evaluated for the severity of redness and inflammation (score 0 to 4). Method of measurement: Scoring severe redness and inflammation using a Reeda questionnaire.;Severe pain and burning. Timepoint: At the beginning of treatment and after every 2 to 10 days, the condition of oral lichen planus lesions is evaluated for the severity of pain and burning (score 0 to 4). Method of measurement: Scoring Severe pain and burning using VAS questionnaire.